- Founded in 1999, we are one of the leading influencers in rheumatology. With our unique focus on translational research we address key clinical challenges and advocate the latest advancements in our field, reaching a large global audience.
- By combining rigorous expert assessment, we provide a swift service with the highest standards.
- 94% of our published authors would resubmit to this journal.
About
Aims and scope
A major focus of the journal is on the immunologic processes leading to inflammation, damage and repair as they relate to autoimmune rheumatic and musculoskeletal conditions, and which inform the translation of this knowledge into advances in clinical care.
Original basic, translational and clinical research is considered for publication along with results of early and late phase therapeutic trials, especially as they pertain to the underpinning science that informs clinical observations in interventional studies.
Why publish your article with Arthritis Research & Therapy?
Open access
All articles published by Arthritis Research & Therapy are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Arthritis Research & Therapy you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article according to the licence terms.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.
Article processing charges (APC)
Authors who publish open access in Arthritis Research & Therapy are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.
The current APC, subject to VAT or local taxes where applicable, is: £2490.00/$3390.00/€2890.00
Visit our open access support portal and our Journal Pricing FAQs for further information.
Open access funding
Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.
Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.
Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.
Indexing services
All articles published in Arthritis Research & Therapy are included in:
- CABI
- CAS
- Current contents
- DOAJ
- Embase
- Global Health
- MEDLINE
- Medscape
- PubMed
- PubMed Central
- Science Citation Index
- Science Citation Index Expanded
- SCImago
- Scopus
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BMC on SpringerLink.
Peer-review policy
Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
Arthritis Research & Therapy operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
Editorial policies
All manuscripts submitted to Arthritis Research & Therapy should adhere to BMC's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Arthritis Research & Therapy
Articles in Arthritis Research & Therapy should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Arthritis Research & Therapy [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Arthritis Research & Therapy 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
Authors who wish to appeal a rejection or make a complaint should follow the procedure outlined in the BMC Editorial Policies.
Benefits of publishing with BMC
High visibility
Arthritis Research & Therapy's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Arthritis Research & Therapy offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Flexibility
Online publication in Arthritis Research & Therapy gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Arthritis Research & Therapy are included in article alerts and regular email updates. Some may be highlighted on Arthritis Research & Therapy’s pages and on the BMC homepage.
In addition, articles published in Arthritis Research & Therapy may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Arthritis Research & Therapy. A list of articles recently press-released by journals published by BMC is available here.
Copyright
As an author of an article published in Cancer & Metabolism you retain the copyright of your article and you are free to reproduce and disseminate your work. For further information, see our guide to licensing, copyright and author rights.
For further information about the advantages of publishing in a journal from BMC, please click here.
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 4.4
5-year Journal Impact Factor: 4.9
Source Normalized Impact per Paper (SNIP): 1.294
SCImago Journal Rank (SJR): 1.518
Speed 2023
Submission to first editorial decision (median days): 9
Submission to acceptance (median days): 111
Usage 2023
Downloads: 3,331,819
Altmetric mentions: 1,885